Hangzhou Sciwind Biosciences Co., Ltd.

ACTIVE

浙江省杭州市, 浙江省, Chinawww.sciwind.com.cnHolding11–50 employeesEstablished: 2017-08-17

Part of beijing junyida biotechnology co., ltd.

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

53.9%

Phase 1

38.5%

Phase 2

7.7%

Trial Status Distribution

Active, not recruiting

7.7%

Completed

53.9%

Not yet recruiting

7.7%

Recruiting

30.8%

Clinical Trials

Trials sponsored by this organization (13)

A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents

Phase 3

Not yet recruiting

interventional

Oct 2026192 participants

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Phase 3

Recruiting

interventional

Aug 2026360 participants

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

Phase 3

Recruiting

interventional

Mar 2026140 participants

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

Phase 3

Recruiting

interventional

Feb 2026140 participants

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Phase 1

Recruiting

interventional

Nov 2025126 participants

A Study of XW003 Injection in Chinese Adolescents With Obesity

Phase 1

Completed

interventional

Aug 202548 participants

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Phase 2

Active, not recruiting

interventional

Jul 2025163 participants

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Phase 1

Completed

interventional

Jul 202357 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations